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Combination of Treatments With or Without Surgery
in Localized Provoked Vulvodynia:
Outcomes After Three Years of Follow-Up
Anu Pauliina Aalto,1,2,* Heini Huhtala,3 Johanna Ma¨enpa¨a¨,1,4 and Synno¨ve Staff1,4
Most vulvodynia patients receive combinations of several treatment modalities for their chronic painful condi-
tion. If conservative treatments fail, vestibulectomy is considered to be the ultimate treatment option for local-
ized provoked vulvodynia (LPV). The aim of this descriptive study was to analyze relief of pain, quality of life (QoL),
and complications associated with combining surgery with conservative treatments among LPV patients, both in
short term and after 3 years of follow-up.
The study population consisted of a retrospective patient cohort of surgically (n = 16) and only conservatively
(n = 50) treated LPV patients. QoL data were assessed by a validated questionnaire (RAND-36). Data were col-
lected by reviewing patient records and by aid of postal questionnaires. Efﬁcacy of treatments in relief of pain
was measured by numerical rating scale (NRS). Two months after surgery, the NRS scores assessed by a physician
were lower in the surgery group than in patients treated only conservatively ( p = 0.008). However, after a median
of 36 months of follow-up, self-reported NRS scores and QoL showed no difference between the two patient
cohorts. Complication rate after vestibulectomy was 18.8%. The ﬁndings suggest that combining surgery with
conservative treatments may result in a more effective short-term reduction of pain. However, the effect seemed
to be only temporary, as no long-term beneﬁt was achieved.
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Introduction
Vulvodynia is a chronic pain syndrome of unknown
etiology affecting 7–8% of women in population-
based epidemiological studies.1,2 Vulvodynia is usually
described as burning, stabbing, itching, stinging, and
feeling of irritation. The 2015 Consensus and Ter-
minology and Classiﬁcation of Persistent Vulvar Pain
and Vulvodynia3 divides vulvar pain into two categories.
The ﬁrst category includes vulvar pain that is caused by a
speciﬁc clearly identiﬁable disorder (e.g., pain caused by
genital herpes). The second category includes vulvar pain
that is at least 3 months in duration and cannot be clearly
identiﬁed or linked to a speciﬁc cause. However, it may
have potential associated factors. The descriptors of the
pain are location (local, generalized, and mixed), type
(provoked, spontaneous, or mixed), onset (primary and
secondary), and temporal pattern (intermittent, persis-
tent, constant, immediate, and delayed). Symptoms can
overlap and co-occur. Vulvodynia may be associated
with a history of yeast infection, hormonal factors, ge-
netic factors, pelvic ﬂoor dysfunction, and psychological
factors.3
The most common clinical subtype of vulvar pain in
premenopausal women is localized provoked vulvody-
nia (LPV).4 LPV is also considered to be the most com-
mon form of sexual pain in women <30 years of age.5
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Chronic pain is known to have a negative impact on a
woman’s quality of life (QoL).6,7
Different medical treatment modalities for LPV con-
sist of local, topical, or oral medications. Patients trea-
ted by a multidisciplinary team are usually offered
physiotherapy (including transcutaneous electrical
nerve stimulation), sexual counseling and therapy,
and psychotherapy. Although a multidisciplinary ap-
proach to LPV is recommended,8,9 it is actually not ev-
idence based.10 Surgery (vestibulectomy) for LPV is
recommended as the ultimate treatment option, if con-
servative treatments fail or are insufﬁcient in terms of
pain reduction.
Based on studies concerning surgical treatment for
LPV, reported success rates vary between 60% and
90%,11 even though the comparison of different studies
is difﬁcult as the term ‘‘success,’’ the surgical technique
used and the length of follow-up show considerable var-
iation.11 There is no deﬁnitive consensus as to which
surgical technique is the superior one. In a review by
Tommola et al.,12 which was based on 33 studies on
surgical treatment for LPV (or vulvar vestibulitis), it
was concluded that the experience of individual sur-
geons plays an important role, and that the aim of
surgery should be to remove all painful tissues while
avoiding unnecessary risks. The review also found sur-
gery to be effective and safe.12
Most studies on surgical treatment for LPV lack ran-
domization and/or controls. One of the few random-
ized controlled studies on vestibulectomy is that by
Bergeron et al.,13 which showed that vestibulectomy
was more successful than surface electromyographic
feedback and group cognitive-behavioral therapy in
pain reduction. As the authors stated, there is a concern
in interpreting these results, due to a higher pretreat-
ment drop-out rate in the vestibulectomy group.13
However, the psychological and sexual functions
remained equally positive in all three groups after 6
months of follow-up. Another study that included ran-
domization to the surgical (behavioral treatment and
surgery) and nonsurgical (behavioral treatment only)
groups, byWeijmar Schultz et al.,14 found no difference
in the outcomes between these two treatment modali-
ties after a mean of 2.5–3 years of follow-up. In the re-
view of Goldstein et al.,11 surgery was recommended
for LPV after failure of conservative treatments (level
B evidence).
In previous studies concerning surgery for LPV, the
measured outcomes have varied. At least pain reduc-
tion,13,15 dyspareunia,13,16 sexual functioning,13 psycho-
logical distress,15 and patient satisfaction16 have been
measured using questionnaires; moreover, ﬁndings of
physical examination and self-reported symptoms have
also been reported. Psychological well-being,17 quality
of sexual life,17 and sexual and partnership satisfaction
have all been reported to improve18 after vestibulectomy.
The aim of this study was to evaluate the safety and
effectiveness of LPV treatments with or without sur-
gery in both short and long terms. Pain was measured
by numerical rating scale (NRS) assessed by both a
physician and the patient. QoL was evaluated after a
combination of treatments with or without surgery,
using a questionnaire (RAND-36) validated in the
Finnish population.
Materials and Methods
This retrospective cohort study on LPV patients was
carried out at the Department of Obstetrics and Gyne-
cology of Tampere University Hospital (TAUH),
Tampere, Finland. All at least 18-year-old women diag-
nosed with vulvodynia at TAUH from January 2003 to
May 2016 were screened for the study. Potential vulvo-
dynia patients were identiﬁed from the hospital records
(computer database) by using the appropriate ICD-10
codes: N90.9 (noninﬂammatory disorder of vulva and
perineum, unspeciﬁed); N90.8 (other speciﬁed nonin-
ﬂammatory disorders of vulva and perineum); N94.1
(dyspareunia); and N94.2 (vaginismus). Only LPV pa-
tients who fulﬁlled the strict criteria by Friedrich,19 or
severe pain on vestibular touch or attempted vaginal
entry, and tenderness on localized pressure within the
vulvar vestibule, were considered eligible (n= 66).
Among these eligible patients, 16 patients operated
on for LPV (vestibulectomy) were identiﬁed. Patients
with generalized or continuous vulvar pain were ex-
cluded. Other exclusion criteria included malignant
tumors of vulva and ongoing inﬂammatory or derma-
tological diseases of vulva. The ﬂow chart of study pa-
tients is shown in Figure 1.
Information on parity, menopausal status, age, differ-
ent treatment modalities, and complications after sur-
gery was collected from the hospital’s medical records.
The baseline pain before any treatments for LPV was
assessed by a physician with a cotton swab test and
rated on an NRS from 0 to 10. If the rating was not
found in the patient record, the information was
reported as ‘‘no data.’’ As a part of the treatment proto-
col, every patient had a checkup appointment at 2
months after the surgical treatment with the operating
surgeon. Patients treated with conservative methods
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only were assessed by a physician usually after 2 or 3
months after commencing the treatments. The conser-
vative treatment modalities used for LPV are described
in Table 1.
The surgical technique used was the modiﬁed poste-
rior vestibulectomy described by Tommola et al.,16 with
the aim to surgically remove the painful vulvar area. The
operations were performed under general anesthesia,
and all operations were carried out by three senior gyne-
cological surgeons. First, 0.01% lidocain cum adrenalin
solution was injected into the vulvar vestibulum for
bleeding control and prevention of postoperative pain.
To excise vestibular mucosa, 2-mm deep incisions
using electrocautery were made from 10 to 2 o’clock
in the posterior vulvar vestibulum to a width of *1–
2 cm. The inner incision was made just inside the hy-
menal ring, and the outer margin followed the Hart’s
line. The vaginal mucosa was liberated from underlying
tissue and subsequently opposed to distal vulvar margin
with absorbable sutures without tension.
A seven-page postal questionnaire on demographic
data, self-reported pain, and RAND-36 was sent to
the 66 eligible LPV patients. The questionnaire was re-
sent to the patients who did not return the question-
naire within 2 months after the ﬁrst mailing.
The validated Finnish version of the RAND-36-item
health survey includes eight multi-item dimensions:
general health, physical functioning, mental health, so-
cial functioning, vitality, pain, and physical and emo-
tional role functioning.20,21
Participants of the study were moreover asked to as-
sess vulvar pain intensity upon touch on the NRS be-
fore and after treatments. NRS was used to quantify
the intensity of vulvar pain by rating the pain using a
0-to-10 scale, where 0 indicates ‘‘no pain’’ and 10 indi-
cates ‘‘the worst pain imaginable.’’
The study protocol was approved by TAUH Ethical
Committee (5APR2016, Identiﬁcation Code R16053),
and a written informed consent was obtained from
the patients participating in this study.
Version 23 of IBM SPSS statistics software was used
in statistical analyses (IBM SPSS Statistics for Win-
dows, Version 23.0. IBM Corp. 2015. Armonk, NY).
Mann–Whitney U-test was used for statistical compar-
isons. A probability value of p < 0.05 was considered as
statistically signiﬁcant.
Results
Thirty-six patients (55%) returned the questionnaire
during the study period (August 2016–November
2016). Twenty-eight patients returned the questionnaire
after the ﬁrst mailing and eight patients after the second
mailing. The patient ﬂow chart is shown in Figure 1. The
response rate to postal questionnaires in the nonsurgical
group was 46.0% and that in the surgical group was
81.3% ( p= 0.020). Demographic data and pain before
and after the treatments are shown in Table 1. At the
data analysis point 1 (2 months after commencing the
treatments), the surgical and nonsurgical groups dif-
fered signiﬁcantly in age ( p= 0.048). The median
follow-up time at the data analysis point 2 was 36
months (interquartile range [IQR]= 24–36). The most
frequent (received by >50% of the patients) combination
of conservative treatments consisted of local treatments
(lidocaine and/or gabapentin), physiotherapy, and sex-
ual counseling in both patient cohorts. The treatment
modalities used for both patient groups are summarized
in Table 1. At the data analysis point 1, the nonsurgical
and surgical treatment groups did not differ with respect
to any treatment modality. However, at the data analysis
point 2, the two treatment groups differed with respect
to the frequency of sexual counseling (Table 1; p= 0.03).
At data analysis point 1, median pretreatment NRS
scores were similar between nonsurgical (i.e., combina-
tion of treatments without surgery) and surgical groups
FIG. 1. Patient ﬂow chart.
Aalto, et al.; BioResearch Open Access 2019, 8.1
http://online.liebertpub.com/doi/10.1089/biores.2018.0044
27
(median NRS scores 9 in both groups, p= 0.11, Table 1).
Median post-treatment NRS score assessed by a physi-
cian in different treatment groups was 7 and 2, respec-
tively ( p= 0.008). After median of 36 months of
follow-up, self-reported NRS scores before or after treat-
ments did not differ signiﬁcantly between the groups
( p= 0.66 and p= 0.18, respectively, Table 1). At data
analysis point 2, we also compared medical record-
derived data assessed by a physician. Physician-assessed
NRS score before treatment in the nonsurgical group
was 8 and that in the surgical group was 9 ( p= 0.014).
Similarly, post-treatment NRS score assessed by a physi-
cian was 7 and 2, respectively ( p= 0.005). Among the
LPV patients who did not respond to postal question-
naires (n= 30), the median pretreatment NRS score col-
lected from the patient records was 9 (IQR= 8–9.5,
missing data n= 13), and the median 2-month post-
treatment NRS score was 5 (IQR= 2.25–8, missing
data n= 14). When nonresponders were compared
with all LPV patients who returned the questionnaire
(data analysis point 2), the pre- and post-treatment
NRS scores derived from the medical records were sim-
ilar ( p= 0.291, p= 0.592, respectively).
The QoL after a median of 36 months of follow-up
after treatments did not differ signiﬁcantly between the
surgical and nonsurgical groups in any of the eight
multi-item dimensions (Table 2 and Fig. 2).
Out of 16 patients operated on, 3 had complica-
tions after surgery, resulting in a complication rate of
18.8%. One patient had heavy postoperative pain and
Table 1. Demographic Data and Treatments Given to Localized Provoked Vulvodynia Patients
Data analysis point 1 (Fig. 1).
Review of medical records
Data analysis point 2 (Fig. 1).

















Number of patients 66 50 16 N/A 36 23 13 N/A
Age, median (IQR) 28 (25–33) 27 (24–32.3) 30.5 (26.5–38.3) 0.048 28.5 (25–32) 27 (24–29) 29 (26.5–33) 0.06
Nulliparous, % (n) 95.5 (63) 94 (47) 100 (16) 0.32 86 (31) 82.6 (19) 92.3 (12) 0.48
Premenopausal, % (n) 98.5 (65) 100 (50) 93.8 (15) 0.08 100 (36) 100 (23) 100 (13) 1.00
NRS before treatments,
asked from patients
at the time of the
cotton-swab test
9 (7.25–9),
n.d. n = 22
9 (7–9),
n.d. n = 18
9 (8–9.5),










at the time of the
cotton-swab test
5 (2–8),
n.d. n = 24
7 (4–8),
n.d. n = 19
2 (2–4),
n.d. n = 5
0.008 5 (2–7),















N/A N/A N/A N/A 3 (2–5.75) 4 (3–6) 2 (2–5) 0.18
Treatments received by LPV patients
Local treatments,b % (n) 100 (66) 100 (50) 100 (16) 1.00 100 (36) 100 (23) 100.0 (13) 1.00
TCA or anticonvulsantc 15.2 (10) 12.0 (6) 25.0 (4) 0.21 16.7 (6) 13.0 (3) 23.1 (3) 0.35
Physiotherapy
(including TENS)
90.9 (60) 92.0 (46) 87.5 (14) 0.59 88.9 (32) 91.3 (21) 84.6 (11) 0.46
Sexual counseling
by a trained nurse
75.8 (50) 80.0 (40) 62.5 (10) 0.16 77.8 (28) 87.0 (20) 61.5 (8) 0.03
Topical treatmentsd 22.7 (15) 18.0 (9) 37.5 (6) 0.11 19.4 (7) 8.7 (2) 38.5 (5) 0.050
Local injections to
the painful sitee
16.7 (11) 16.0 (8) 18.8 (3) 0.80 11.1 (4) 8.7 (2) 15.4 (2) 0.76
ap-value between surgical and nonsurgical groups.
bLidocaine gel to the painful area in vulva 30min before intercourse or gabapentin 6% cream applied twice a day to the painful area for 6–8 weeks.
cAmitriptyline 10–40mg most commonly used TCA or pregabalin 150–300mg.
dPodophyllotoxin (5mg/mL) applied locally to tender points of vestibulum after 5% acetic acid application. Treated area was covered with a mild
estrogen cream and covered with gauze pads until the next day.
e2–4mL of betametasone and long acting anesthetic agent (bupivacaine), both 50% and 50%, injected submucuously to the painful site.
IQR, interquartile range; LPV, localized provoked vulvodynia; N/A, not applicable; n.d., no data; NRS, numerical rating scale; TCA, tricyclic antide-
pressant; TENS, transcutaneous electrical nerve stimulation.
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was readmitted to hospital on the third postoperative
day. Two months after surgery, the patient was still suf-
fering from pain, whereas after 1 year of follow-up the
pain in the vulvar area was ‘‘transformed into a neuro-
pathic pain,’’ and the patient was treated with peroral
gabapentin, which resulted in sufﬁcient pain relief.
Another patient was readmitted after 7 days of surgery,
because of a partial wound dehiscence. The wound was
reported to have healed completely at the 2-month
follow-up visit. The third patient suffered from severe
pain right after surgery, and had to stay overnight at
the hospital. At 2-month follow-up, the pain score was
assessed as ‘‘0’’ by the operating physician.
Discussion
We describe here a retrospective cohort of 66 LPV
patients treated at our institution. We evaluated short-
term surgical complications, pain, and QoL of nonsur-
gically and surgically treated patients ﬁrst after 2
months and then after a median of 36 months of
follow-up. QoL after 36 months did not differ when
comparing the surgically and only conservatively trea-
ted groups in any of the eight QoL dimensions of val-
idated RAND-36 questionnaire. Addition of surgery to
the conservative treatments resulted in lower NRS
scores measured by a physician 2 months after surgery.
However, there was no difference in self-reported NRS
pain scores measured after the longer follow-up.










95.4 (15.20) 92.4 (14.45) 0.243
Physical role functioning,
mean (SD)
84.6 (33.13) 69.6 (43.92) 0.278
Emotional role functioning,
mean (SD)
66.7 (40.82) 56.5 (46.53) 0.498
Vitality, mean (SD) 58.1 (16.65) 51.5 (23.95) 0.518
General mental health,
mean (SD)
68.9 (22.87) 65.7 (21.77) 0.416
Social functioning, mean (SD) 79.8 (19.46) 72.3 (27.94) 0.485
Pain, (SD) 75.2 (26.76) 64.7 (24.50) 0.144
General health perceptions,
mean (SD)
63.9 (21.03) 62.2 (23.88) 0.974
ap-value between surgical and nonsurgical treatment groups.
SD, standard deviation.
FIG. 2. Quality of life of LPV patients measured with RAND-36. LPV, localized provoked vulvodynia.
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Vestibulectomy seems to be a safe treatment modality
for LPV with an acceptable complication rate. This is in
line with the previous review by Tommola et al. concern-
ing surgery for LPV.12 In this study, surgery was associ-
ated with better short-term outcomes in terms of pain
after 2 months of surgery. Previously, it has been
shown that median pain measured with VAS decreases
from 8 to 2 in surgically treated patients,18 which is of
a magnitude similar to our results. However, assessment
of pain at the checkup visits shortly or at any time point
after surgery by the attending surgeon is not blinded and
certainly at risk of many types of bias. This bias may also
explain the differences shown here between NRS values
obtained frommedical records and those reported by pa-
tients themselves. In a randomized study,14 surgical in-
tervention added to behavioral approach had outcome
similar to behavioral approach after 2.5–3 years of
follow-up. A similar outcome was found among patients
given an opportunity to choose between surgery and no
surgery. Although the sample size in the study was small
(n= 14 in the randomized part of the study), it being a
randomized study strengthens the perception that indi-
vidual tailoring of treatment is one of the key factors in
a successful treatment for LPV.
We report here QoL data obtained with a validated
questionnaire among surgically and nonsurgically
treated vulvodynia patients. There was no difference
in QoL between these two patient groups after a me-
dian of 3 years of follow-up. Previously, Bohm-Starke
and Rylander have reported that vestibulectomy im-
proves QoL measured by VAS from median 0.5 to
6.5, during a median 41 months of follow-up.17 How-
ever, another long-term follow-up study on LPV pa-
tients treated conservatively versus treated surgically
failed to show any difference in long-term well-
being between the treatment groups.18 Even if there
are previous valuable reports on QoL and overall
well-being among vestibulectomy patients,17,18 to
our knowledge this is the ﬁrst report using a validated
QoL questionnaire when assessing QoL among vesti-
bulectomy patients.
There are some limitations to our study. The study
is a retrospective nonrandomized cross-sectional
study. An ideal study setting would have been a com-
parison between only surgically and nonsurgically
treated patients preferably as a randomized con-
trolled study. A confounding factor is that the study
patients in the surgical group had also received vari-
ous conservative treatments before surgery, that is,
the comparison between the groups is in fact a com-
parison between combination of treatments with and
without surgery. Because both groups received vari-
ous conservative treatment modalities it is not possi-
ble to conclude fully the effectiveness of surgery.
However, this setting is clinically unavoidable since
vestibulectomy is the treatment modality offered to
patients only after failure of all noninvasive treat-
ments. The fact that patients were asked to report
pain retrospectively after a median of 36 months
after treatments contains also a risk of bias. However,
the median follow-up time after treatments did not
differ signiﬁcantly between surgically and nonsurgi-
cally treated patients ( p = 0.35) and QoL measured
corresponded to present moment (i.e., the time of
questionnaire). A longitudinal QoL evaluation, done
before and after treatments, would have been of addi-
tional value.
Although the total number of patients is relatively
low, with the surgically treated group being even
smaller, it reﬂects the fact that vulvodynia is a rather
rare condition. The response rate after follow-up was
only satisfactory, 55%. The response rate to postal ques-
tionnaires of surgically treated patients was higher and
this may lead to a false accentuation of positive effect
of the intervention, that is, to a type I error. However,
pain rated on the NRS and QoL did not differ signiﬁ-
cantly between the groups after the longer follow-
up. The amount of missing data was unfortunately
also quite high and this may cause bias. The study pa-
tients had received slightly different conservative treat-
ment entities before surgery or during the treatment
period that might have an effect on outcome, too.
Conclusion
Measuring QoL with a validated questionnaire in the
Finnish population can be considered as strength of
the study. Bearing in mind the limitations, as dis-
cussed earlier, we conclude that even if surgery
seems to be associated with more effective pain man-
agement in the short term, it showed no additional
beneﬁt with respect to QoL or pain after extended
follow-up. In contrast, it may be concluded that per-
forming vestibulectomy after conservative treatments
is safe and does not seem to be harmful. However,
long-term patient-reported outcomes in terms of
QoL and pain after surgery do not seem to differ
from those achieved conservatively. Considering re-
cent evidence of a strong placebo effect concerning
medical treatments,22 prospective sufﬁciently pow-
ered controlled trials are truly warranted.
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VAS ¼ visual analogue scale
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